after teaching courses in Brazil. I still see that CTT is a one-product company; that Nano is entitled to $750,000; that the Scott lawsuit is still pending; and that the employee count is way down. It appears that a select few are merely clipping coupons until the coompany folds.
for your information, alumilli has been a long time poster on the CTT board, but also a very bitter poster whose identity is, to some extent, revealed by the monicker, i.e., University of ILLInois ALUMnus. However, many of us have suspected several points: 1) not a female 2) someone who had a lot to do with an early patent that the original firm University Patents was marketing, etc, specifically the Plato system developed at U of Ill -Urbana
Most of the time this poster emerges from his/her cave to bash a company that has morphed so many times it is a wonder he has anyone to hate there anymore other than persisting in this bitterness aimed, believe it or not, at someone who preceded Nano by several generations. This is more like a Hatfield-McCoy fued where no one recalls what started it, although I am sure alumilli, if he/she wanted to, could tell all. Instead, you have the bi-annual bashing before this groundhog goes back into the den and hibernates once more
1. Scrambler Therapy May Relieve Chronic Neuropathic Pain More Effectively Than Guideline–Based Drug Management: Results of a Pilot, Randomized, Controlled Trial Journal of Pain and Symptom Management 2. A Comparative Efficacy of Amitriptyline, Gabapentin, and Pregabalin in Neuropathic Cancer Pain: A Prospective Randomized Double–Blind Placebo–Controlled Study American Journal of Hospice and Palliative Medicine 3. Duloxetine, Pregabalin, and Duloxetine Plus Gabapentin for Diabetic Peripheral Neuropathic Pain Management in Patients With Inadequate Pain Response to Gabapentin: An Open–Label, Randomized, Noninferiority Comparison Mayo Clinic Proceedings >>See the rest of this Month's Top Read